142 related articles for article (PubMed ID: 29100024)
1. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
[TBL] [Abstract][Full Text] [Related]
2. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
[TBL] [Abstract][Full Text] [Related]
3. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J
Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
Leitch C; Osdal T; Andresen V; Molland M; Kristiansen S; Nguyen XN; Bruserud Ø; Gjertsen BT; McCormack E
Oncotarget; 2016 Feb; 7(7):8105-18. PubMed ID: 26812881
[TBL] [Abstract][Full Text] [Related]
8. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
[TBL] [Abstract][Full Text] [Related]
9. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Kruczynski A; Pillon A; Créancier L; Vandenberghe I; Gomes B; Brel V; Fournier E; Annereau JP; Currie E; Guminski Y; Bonnet D; Bailly C; Guilbaud N
Leukemia; 2013 Nov; 27(11):2139-48. PubMed ID: 23568148
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of artemisinins for the treatment of acute myeloid leukemia.
Drenberg CD; Buaboonnam J; Orwick SJ; Hu S; Li L; Fan Y; Shelat AA; Guy RK; Rubnitz J; Baker SD
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1231-43. PubMed ID: 27125973
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Leonard SM; Perry T; Woodman CB; Kearns P
PLoS One; 2014; 9(1):e87475. PubMed ID: 24489920
[TBL] [Abstract][Full Text] [Related]
13. A Natural Combination Extract of Viscum album L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML In Vivo.
Delebinski CI; Twardziok M; Kleinsimon S; Hoff F; Mulsow K; Rolff J; Jäger S; Eggert A; Seifert G
PLoS One; 2015; 10(8):e0133892. PubMed ID: 26244918
[TBL] [Abstract][Full Text] [Related]
14. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
Gopalakrishnapillai A; Kolb EA; McCahan SM; Barwe SP
Leuk Res; 2017 Jul; 58():91-97. PubMed ID: 28505595
[TBL] [Abstract][Full Text] [Related]
16. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Khoury H; He R; Schimmer A; Beadle JR; Hostetler KY; Minden MD
Chemotherapy; 2018; 63(4):225-237. PubMed ID: 30372692
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
Xie C; Edwards H; Xu X; Zhou H; Buck SA; Stout ML; Yu Q; Rubnitz JE; Matherly LH; Taub JW; Ge Y
Clin Cancer Res; 2010 Nov; 16(22):5499-510. PubMed ID: 20889917
[TBL] [Abstract][Full Text] [Related]
20. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
